Managing ADHD Symptoms in Patients with a History of Substance Abuse

Medication Management Options

The American Academy of Pediatrics recommends considering long-acting stimulant formulations with lower abuse potential, such as lisdexamfetamine (Vyvanse) or OROS methylphenidate (Concerta), for patients with ADHD and a history of substance abuse who are no longer responding to bupropion 1, 2
Lisdexamfetamine (Vyvanse) contains dextroamphetamine with a lysine molecule that is only activated after ingestion, making extraction difficult, as noted by the Pediatrics journal 2
OROS methylphenidate (Concerta) has a delivery system that makes extraction of the stimulant more difficult, according to the Pediatrics journal 2
Dermal methylphenidate (Daytrana) has a transdermal delivery system that reduces abuse potential, as reported by the Pediatrics journal 2
Atomoxetine (Strattera) is a norepinephrine reuptake inhibitor with no abuse potential, recommended by the Pharmacology and Therapeutics journal and the Praxis Medical Insights guideline 1, 3
Extended-release guanfacine (Intuniv) or extended-release clonidine (Kapvay) are alpha-2 adrenergic agonists with no abuse potential, as noted by the Pediatrics journal 2

Regular urine drug screening should be implemented to ensure compliance and detect any return to substance use, as recommended by the Praxis Medical Insights guideline 1
Monthly follow-up visits should be scheduled to assess response to medication changes, according to the Praxis Medical Insights guideline 1
Patients should be assessed for development of new psychiatric comorbidities that might be contributing to worsening ADHD symptoms, as recommended by the Praxis Medical Insights guideline 1
Side effects of new medications, particularly stimulants, should be monitored, as noted by the Praxis Medical Insights guideline 1

Cognitive-behavioral therapy should be added to medication management to address both ADHD symptoms and substance use patterns, as recommended by the Praxis Medical Insights guideline 1
Skills training for ADHD symptom management should be implemented, according to the Praxis Medical Insights guideline 1
Lifestyle modifications, such as regular sleep schedule, stress management techniques, and regular exercise regimen, can enhance medication effectiveness, as recommended by the Praxis Medical Insights guideline 1

A history of substance abuse is not an absolute contraindication to stimulant use, but requires careful monitoring, as noted by the Journal of the American Academy of Child and Adolescent Psychiatry 4
Concomitant use of MAO inhibitors with stimulants or bupropion should be avoided due to risk of severe hypertension and potential cerebrovascular accidents, as reported by the Journal of the American Academy of Child and Adolescent Psychiatry and the Praxis Medical Insights guideline 1, 4
Patients with ADHD may respond to either amphetamine or methylphenidate with an overall very high response rate when both types are tried, according to the Pharmacology and Therapeutics journal 3

A single antidepressant should not be assumed to effectively treat both ADHD and any comorbid depression, as noted by the Praxis Medical Insights guideline 1
Bupropion can cause headache, insomnia, and anxiety as side effects, which might be mistaken for returning ADHD symptoms, according to the Praxis Medical Insights guideline 1
Mixed agonist-antagonist medications should be avoided as they may precipitate withdrawal in patients with a history of substance dependence, as recommended by the Praxis Medical Insights guideline 1
Ineffective treatments should not be continued without periodic reassessment, as guidelines recommend that patients with ADHD should be periodically assessed to determine continued need for treatment, according to the Pharmacology and Therapeutics journal 3